- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 15:26 | OSR Holdings, Inc.: OSR Holdings Eliminates $2.02 Million Warrant Overhang with Premium-Priced Convertible Note | 176 | ACCESS Newswire | BELLEVUE, WA / ACCESS Newswire / April 9, 2026 / OSR Holdings, Inc. (NASDAQ:OSRH) ("OSR Holdings" or the "Company") today announced a strategic transaction for capital structure optimization with White... ► Artikel lesen | |
| 02.04. | OSR Holdings und BCM Europe: Neue Lizenzvereinbarung für VXM01 sichert Zahlungen von bis zu 815 Mio. $ | 2 | Investing.com Deutsch | ||
| OSR HOLDINGS Aktie jetzt für 0€ handeln | |||||
| 02.04. | OSR Holdings, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 31.03. | OSR Holdings, Inc. - 10-K, Annual Report | - | SEC Filings | ||
| 30.03. | OSR Holdings, Inc.: OSR Holdings to Update Investors at the Emerging Growth Conference on April 1, 2026 | 130 | ACCESS Newswire | BELLEVUE, WA / ACCESS Newswire / March 30, 2026 / OSR Holdings, Inc. (NASDAQ:OSRH), a global healthcare holding company advancing biomedical innovations to improve health and wellness worldwide, today... ► Artikel lesen | |
| 27.03. | Emerging Growth Research Issues Flash Report on OSR Holdings, Inc., Reaffirms Buy-Emerging Rating and $10.00 Price Target | 304 | ACCESS Newswire | NEW YORK CITY, NY / ACCESS Newswire / March 27, 2026 / Emerging Growth Research today issued a flash report on OSR Holdings, Inc. (Nasdaq:OSRH), reaffirming its Buy-Emerging rating and 12-month price... ► Artikel lesen | |
| 23.03. | OSR Holdings, Inc.: OSR Holdings Updates $815 Million VXM01 Licensing Deal Structure to Capture Value at Parent Level | 261 | ACCESS Newswire | BELLEVUE, WA / ACCESS Newswire / March 23, 2026 / OSR Holdings, Inc. (NASDAQ:OSRH) today announced an updated structure of its previously disclosed binding term sheet dated January 13, 2026 with BCM... ► Artikel lesen | |
| 19.03. | OSR Holdings, Inc.: Woori IO, an OSR Company, Signs NDA with Sinopharm to Explore China Commercial Opportunities | 479 | ACCESS Newswire | BELLEVUE, WA / ACCESS Newswire / March 19, 2026 / OSR Holdings, Inc. (NASDAQ:OSRH), a healthcare-focused holding company advancing innovative medical technologies, today announced that its subsidiary... ► Artikel lesen | |
| 10.03. | OSR Holdings, Inc. - 8-K, Current Report | 4 | SEC Filings | ||
| 05.03. | OSR Holdings secures 180-day extension from Nasdaq | 3 | Seeking Alpha | ||
| 05.03. | Nasdaq grants OSR Holdings extension to regain compliance | 2 | Investing.com | ||
| 05.03. | OSR Holdings, Inc. Granted 180-Day Nasdaq Extension; Reaffirms Strategic Momentum | 562 | ACCESS Newswire | BELLEVUE, WASHINGTON / ACCESS Newswire / March 5, 2026 / OSR Holdings, Inc. (NASDAQ:OSRH), a global healthcare holding company advancing innovative biomedical technologies, today announced that it has... ► Artikel lesen | |
| 02.02. | OSR Holdings, Inc.: CEO Statement to Shareholders | 351 | ACCESS Newswire | BELLEVUE, WASHINGTON / ACCESS Newswire / February 2, 2026 / Reaffirming Strategic Execution and Long-Term Value CreationAs the compliance deadline under the minimum bid requirement of NASDAQ approaches... ► Artikel lesen | |
| 27.01. | OSR Holdings, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 27.01. | OSR Holdings, Inc.: OSR Holdings Completes Woori IO Acquisition, Secures Long-Term Shareholder Alignment, and Reviews Strategic Combination of Medical Device Subsidiaries | 585 | ACCESS Newswire | BELLEVUE, WA / ACCESS Newswire / January 27, 2026 / OSR Holdings, Inc. (NASDAQ:OSRH) today announced the official closing of its acquisition of Woori IO, the reaffirmation of long-term equity alignment... ► Artikel lesen | |
| 14.01. | OSR Holdings, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 19.12.25 | Woori IO shareholders approve final step in OSR Holdings acquisition | 5 | Investing.com | ||
| 19.12.25 | Woori IO-Aktionäre stimmen Übernahme durch OSR Holdings zu | 2 | Investing.com Deutsch | ||
| 19.12.25 | OSR Holdings Inc.: Woori IO Shareholders Approve Share Exchange to Become Wholly-Owned Subsidiary of OSR Holdings | 418 | PR Newswire | Company advancing dual clinical pathways, including a Samsung-supported PoC trial in Korea and a planned U.S. FDA trial with a leading California research university
... ► Artikel lesen | |
| 04.12.25 | Emerging Growth Research Issues Flash Report on OSR Holdings, Inc., Reaffirms Buy-Emerging Rating and $10.00 Price Target Following Major Licensing Agreement | 464 | Newsfile | New York, New York--(Newsfile Corp. - December 4, 2025) - Emerging Growth Research today issued a flash report on OSR Holdings, Inc. (NASDAQ: OSRH), reaffirming its Buy-Emerging rating and 12-month... ► Artikel lesen |
1 2 Weiter >>
39 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| PACIFIC BIOSCIENCES OF CALIFORNIA | 1,205 | -4,10 % | PacBio Announces the Appointment of Chris Gibson to the Board of Directors | MENLO PARK, Calif., March 05, 2026 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a leading provider of high-quality, long-read sequencing technologies, today announced the appointment of Christopher... ► Artikel lesen | |
| CYTOMX THERAPEUTICS | 3,708 | +2,15 % | CYTOMX THERAPEUTICS INC zeigt nachhaltige Stärke | ||
| CARISMA THERAPEUTICS INC | 0,127 | -100,00 % | CSE Bulletin: Name and Symbol Change - Carmanah Minerals Corp. (CARM) | Le 7 avril/April 2026
Carmanah Minerals Corp. (CARM) has announced a name and symbol change to Skull Ridge Gold Corp. (SKUL).
Shares will begin trading under the new name and symbol and with a... ► Artikel lesen | |
| CAPRICOR | 27,530 | +1,66 % | Capricor Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update | Deramiocel BLA for Duchenne muscular dystrophy under U.S. FDA review with PDUFA target action date of August 22, 2026Pivotal HOPE-3 Phase 3 trial achieved primary endpoint (PUL v2.0) and key secondary... ► Artikel lesen | |
| CORMEDIX | 6,292 | +1,32 % | CorMedix, Inc.: CorMedix Inc. Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update | - Q4 2025 Net Revenue of $128.6 million - Pro Forma Full Year 2025 Net Revenue of $401.3 million - Q4 2025 Net Income of $14.0 million; Adjusted EBITDA of $77.2 million - Conference Call Scheduled... ► Artikel lesen | |
| MINERVA NEUROSCIENCES | 4,482 | -1,49 % | Minerva Neurosciences, Inc: Minerva Announces Leadership Transition | Jim O'Connor joins as Chief Business Officer and General CounselBURLINGTON, Mass., April 02, 2026 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company... ► Artikel lesen | |
| REPLIMUNE | 5,270 | +4,56 % | FDA Review Looms As Replimune Faces Weak Technical Setup | ||
| VALERIO THERAPEUTICS | 0,117 | 0,00 % | Valerio Therapeutics Announces the Appointment of Professor Eric Vivier as Observer to Its Board of Directors | Regulatory News:
Valerio Therapeutics ("Valerio Therapeutics" or the "Company") (Euronext Growth Paris: ALVIO) announces the appointment of Professor Eric Vivier as an Observer to its Board of... ► Artikel lesen | |
| RANI THERAPEUTICS | 0,782 | -5,88 % | Rani Therapeutics Appoints Dr. Sara Kenkare-Mitra as Strategic Advisor to Advance Platform and Clinical Strategy | SAN JOSE, Calif., April 09, 2026 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. ("Rani Therapeutics" or "Rani") (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery... ► Artikel lesen | |
| IO BIOTECH | 0,048 | 0,00 % | IO Biotech Provides Corporate Update | Raymond James engaged as financial advisorReduction in force implemented NEW YORK, Jan. 30, 2026 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing... ► Artikel lesen | |
| ALTO NEUROSCIENCE | 22,145 | +1,72 % | H.C. Wainwright reiterates Alto Neuroscience stock rating at buy | ||
| CERO THERAPEUTICS | 0,095 | +0,11 % | CERo Therapeutics Holdings, Inc.: CERo Therapeutics Doses Second Patient in Cohort 2 of Phase 1 CER-1236 Trial | Trial advancing with ongoing safety and pharmacologic evaluation and planned expansion into MDS and MF SOUTH SAN FRANCISCO, Calif., March 30, 2026 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc.... ► Artikel lesen | |
| QIAGEN | 35,030 | -1,14 % | QIAGEN N.V.: Qiagen Announces Form 20-F Annual Report Filing for 2025 Results | QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) announced today that it has filed its annual report, including its audited consolidated financial statements on Form 20-F, for the year ended... ► Artikel lesen | |
| EVOTEC | 4,526 | -3,21 % | Evotec Aktie: 2 Euro oder 6 Euro - wohin geht es für die Biotech-Aktie? | Nach dem Absturz der Evotec Aktie an die 4-Euro-Marke läuft bei dem Biotech-Titel ein erneuter Versuch einer Bodenbildung. Die zentrale charttechnische Unterstützung hat sich diesmal im Kern bei 3,995/4... ► Artikel lesen | |
| ONCONETIX | 2,220 | +98,21 % | Onconetix, Inc.: Onconetix Highlights Realbotix's Launch of Vinci AI Vision System with Delivery of First Vinci-Equipped Humanoid Robot to Ericsson |
OSR HOLDINGS INC gehört der Branche Biotechnologie an. Mit einer aktuellen Kursveränderung von +0,013 (+2,56 %) liegt der Kurs bei 0,505 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu OSR HOLDINGS INC finden Sie auf Wallstreet Online.